BSH 2017 | How the treatment of AML will change
Mary F. McMullin
Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
19:31
Utilizing MRD for AML in the clinical setting
Jorge Sierra
et al.
11:42
AML treatment: what does the data say?
Adriano Venditti
et al.
9:08
Biological mechanisms of AML: a 2019 update
Klaus Metzeler
et al.
6:39
Molecular techniques for monitoring MRD in AML
Torsten Haferlach
